NCT06102083View on ClinicalTrials.gov

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

March 1, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

TDI01 suspension

"Experimental group 1:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Experimental group 2:~Drug: TDI01 suspension Administration: TDI01 suspension once daily.~Control group:~Drug: Placebo Administration: Placebo once daily."

All Listed Sponsors
lead

Beijing Tide Pharmaceutical Co., Ltd

INDUSTRY